Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Randomized Trial of a Short Course of Preoperative Potassium Iodide in Patients Undergoing Thyroidectomy for Graves’ Disease
source: American Journal of Surgery
year: 2017
authors: Whalen G, Sullivan M, Maranda L, Quinlan R, Larkin A
summary/abstract:Background:
A short course of potassium iodide (SSKI) has been traditionally used to prepare patients with Graves’ disease for thyroidectomy. The rationale for this treatment has evolved over time; from control of hyperthyroidism to facilitating surgery by making the gland less friable and bloody.
Methods:
Randomized trial of preoperative SSKI vs no SSKI to test whether that is true.
Results:
Mean estimated blood loss in the SSKI group (62 mL) was less than in the control group (162 mL) as was the median estimated blood loss (50 vs 140 mL). Mean (142 vs 162 minutes) and median (138 vs 150 minutes) operative times were also less in the SSKI arm. Subjective difficulty of operation was similar. Multivariable comparisons of groups with analysis of covariance showed the SSKI group suffered a mean blood loss 35% of the no treatment group (P = .036), the 9.2% decrease in Operating Room (OR) time between the SSKI group and the no treatment group was not statistically different (P = .464).
Conclusions:
SSKI given before operation in patients with Graves’ disease reduces blood loss during thyroidectomy.
DOI: 10.1016/j.amjsurg.2016.07.015
read more
myBinderRelated Content
-
Relation Between Therapy for Hyperthyroidism and the Course of Graves’ OphthalmopathyBackground: The chief clinical characte...
-
What is Graves’ Disease? What is Hyperthyroidism? With Doctor David Schneider from University of WisconsinThis episode (interview with Dr. David S...
-
Impact of Potassium Iodide on Thyroidectomy for Graves’ Disease: Implications for Safety and Operative Difficu...Background: Potassium iodide (KI) is of...
-
Treatment Choice, Satisfaction and Quality of Life in Patients With Graves’ DiseaseBackground: Thyrotoxicosis, most often ...
-
New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Mo...Horizon Pharma plc today announced that ...
-
Risk Factors of Hepatic Dysfunction in Patients With Graves’ Hyperthyroidism and the Efficacy of 131iodine Tre...Hepatic dysfunction is often observed in...
-
Quality-of-Life Outcomes in Graves’ Disease Patients After Total ThyroidectomyHistorically, research into surgical tre...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google